ImmunoACT

ImmunoACT is a pioneering biotechnology startup, proudly based in India, that specializes in the development of indigenous Cell & Gene Therapy. Founded in 2018 as a spin-out from IIT-Bombay, the company has quickly established itself as a leader in the field, with a strong focus on addressing unmet medical needs within the country. Their mission revolves around providing affordable access to novel autologous CAR-T cell therapies to a broader patient population, starting with blood cancers. The company has seen significant support from investors, with the latest corporate round investment totaling a substantial INR800.00M, confirmed on 31 May 2023. This injection of funds came from Laurus Labs, consolidating their commitment to ImmunoACT's vision and potential to make a meaningful impact in the biotechnology landscape. ImmunoACT's dedication to innovation and disrupting the status quo in healthcare has positioned them as an attractive prospect for venture capital firms seeking opportunities in the biotechnology sector. As they continue to expand their pipeline and make strides in pioneering cell and gene therapies, their trajectory will undoubtedly be closely monitored by investors looking to align with pioneering ventures in the field.